Learn More
AIM Dapagliflozin is a selective sodium-glucose co-transporter 2 (SGLT2) inhibitor under development as a treatment for type 2 diabetes mellitus (T2DM). This study assessed the efficacy and safety of(More)
Ixabepilone (BMS-247550) is the first in a new class of anti-neoplastic agents, the epothilone analogs, and is a highly active non-taxane anti-microtubule agent. This phase I study aimed to determine(More)
Ipilimumab(MDX-010, BMS-734016)is a fully human monoclonal immunoglobulin(IgG1k)specific for human cytotoxic T lymphocyte antigen 4(CTLA-4, CD152), which is expressed on a subset of activated T-cells(More)
  • 1